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Abstract
Aim The purpose of this study was to translate evidence
from Cochrane Reviews into a format that can be used to
facilitate shared decision making during the consultation,
namely patient decision aids.
Methods A systematic development process (a) established
a stakeholder committee; (b) developed a prototype
according to the International Patient Decision Aid Stan-
dards; (c) applied the prototype to a Cochrane Review and
used an interview-guided survey to evaluate acceptability/
usability; (d) created 12 consult decision aids; and (e) used
a Delphi process to reach consensus on considerations for
creating a consult decision aid.
Results The 1-page prototype includes (a) a title specifying
the decision; (b) information on the health condition,
options, benefits/harms with probabilities; (c) an explicit
values clarification exercise; and (d) questions to screen for
decisional conflict. Hyperlinks provide additional infor-
mation on definitions, probabilities presented graphically,
and references. Fourteen Cochrane Consumer Network
members and Cochrane Editorial Unit staff participated.
Thirteen reported that it would help patient/clinician dis-
cussions and were willing to use and/or recommend it.
Seven indicated the right amount of information, six not
enough, and one too much. Changes to the prototype were
more links to definitions, more white space, and details on
GRADE evidence ratings. Creating 12 consult decision
aids took about 4 h each. We identified ten considerations
when selecting Cochrane Reviews for creating consult
decision aids.
Conclusions Using a systematic process, we developed a
consult decision aid prototype to be populated with evi-
dence from Cochrane Reviews. It was acceptable and easy
to apply. Future studies will evaluate implementation of
consult decision aids.
Electronic supplementary material The online version of this
article (doi:10.1007/s40271-016-0177-9) contains supplementary
material, which is available to authorized users.
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Key Points for Decision Makers
It is feasible to develop a brief patient decision aid
prototype to be used to facilitate shared decision
making in the consultation and also meets the
International Patient Decision Aid Standards
qualifying and certifying criteria.
Several key characteristics of Cochrane Reviews
make it easier and some circumstances make it more
relevant for creating consult decision aids.
Developers need to balance providing adequate
information on the options, benefits and harms while
keeping the consult decision aid brief enough that it
can be used in clinical practice.
1 Background
Health policy in several countries calls for using patient
decision aids to facilitate shared decision making, provide
more patient-centered care, enhance health literacy, and
improve patient safety [1–4]. This demand for patient
decision aids is part of a larger paradigm shift from doctor-
centric decision making to shared decisions with patients
which is achievable if effective implementation interven-
tions such as patient decision aids are used [5]. Patient
decision aids make explicit the decision, provide high-
quality evidence on the outcomes of options including
watchful waiting, and help patients clarify what is impor-
tant to them based on their personal circumstances [6].
Longer formats have been developed and used by patients
in preparation for the consultation with briefer formats
used between patients and clinicians during the consulta-
tion. Compared with usual practice, patients exposed to
decision aids have higher decision quality, increased par-
ticipation in decision making, and lower personal uncer-
tainty concerning the decision to be made (i.e., decisional
conflict) [6]. Those decision aids designed for use in the
consultation are more likely to facilitate shared decision
making discussions between patients and their clinicians
[6, 7]. Despite strong evidence on the effectiveness of
patient decision aids, there are only about 300 up-to-date
ones publicly available for a limited number of health
conditions and most are restricted to English [8].
Evidence from Cochrane systematic reviews could be
used to develop decision aids to inform patient-level deci-
sions and reduce waste in health care by creating tools that
promote the integration of research into everyday clinical
practice [9]. There are over 6000 Cochrane Reviews that
provide high quality evidence, free from industry interests,
on the benefits and harms of options [10, 11]. Most reviews
provide probabilities that can be used to communicate the
chances of both benefits and harms for options; this is known
to improve patients’ realistic expectations [6]. Another
advantage to using evidence from Cochrane Reviews is the
commitment to updates every 2 years which can ensure
patient decision aids are consistent with the latest evidence
[12]. As well, plain language summaries, available in mul-
tiple languages, provide a simpler description of the health
condition and evidence from the Cochrane Review [6, 11].
However, current Cochrane Reviews do not present the
evidence in an interactive format that meets the definition of
a patient decision aid and are not in a user-friendly format to
help patients with understanding the complex probabilistic
nature of the evidence [10]. Current formats contain the full
Cochrane Review, scientific abstract, and consumer sum-
mary. We argue that translation of Cochrane Review evi-
dence into clinical practice would be greatly enhanced if it
was embedded in patient decision aids.
2 Aim
Our overall aim was to translate evidence from Cochrane
Reviews into a format that can be used to facilitate shared
decision making during the consultation, namely patient
decision aids. The specific objectives were to (a) develop
and evaluate a prototype for a consult decision aid that is
acceptable and usable; (b) apply the prototype to develop a
series of 12 consult decision aids; and (c) identify con-




We used a systematic development process that was guided
by the Ottawa Decision Support Framework and the
International Patient Decision Aid Standards (IPDAS) [11,
13, 14]. The process involved (a) establishing an expert
committee of stakeholders; (b) developing the prototype
for a consult decision aid; (c) conducting alpha testing with
potential users; (d) applying the prototype to 12 Cochrane
Reviews; and (e) reaching consensus on considerations for
including consult decision aids in a Cochrane Review.
Ethics approval was obtained from the Ottawa Hospital
Research Ethics Boards (20130926-01H).
3.2 Theoretical Frameworks
We used IPDAS and the Ottawa Decision Support
Framework. The IPDAS Collaboration established an
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evidence-informed framework for enhancing the quality
and effectiveness of patient decision aids [15]. Over 100
stakeholders (e.g., researchers, policy makers, patients,
clinicians, patient decision aid developers) from 14 coun-
tries reached consensus on 74 items in the IPDAS checklist
[10]. The IPDAS checklist was transformed into a 47-item
instrument [16]. More recently, IPDAS criteria were
triaged into proposed qualifying (6 items), certifying (6
items plus 4 items for screening decisions), and quality
criteria (28 items) [11]. For example, criteria for qualifying
as a patient decision aid are explicitly stating the decision,
providing information on the health condition and options,
describing the positive and negative features of options,
and helping patients clarify their values.
The Ottawa Decision Support Framework is an evi-
dence-based mid-range theory for supporting patients
making health or social decisions [14, 17, 18]. It was
informed by theoretical concepts from psychology, deci-
sion analysis, decisional conflict, social support, and eco-
nomics. This framework is most commonly used for
developing and evaluating patient decision aids [18]. It has
also been used to develop clinician decision support
resources and tools to evaluate the quality and outcomes of
providing patient decision aids [18, 19].
3.3 Stakeholder Committee
Our committee had a range of stakeholders including a
consumer with regular exposure to a variety of consumers
from different settings, clinicians (e.g., nurse, primary care
physician, and rheumatologist), information technology
specialists, and health services researchers with expertise in
patient decision aid development and evaluation, knowl-
edge translation to patients, shared decision making, sys-
tematic reviews, and web-based applications.
3.4 Consult Decision Aid Prototype
We developed a prototype for a patient decision aid that
could be informed by evidence taken directly from
Cochrane systematic reviews. Cochrane Reviews were
chosen because the Cochrane Library has the largest
international set of systematic reviews providing a robust
source of regularly updated evidence free from industry
interests. The patient decision aid was titled a consult
decision aid given a brief 1-page format designed for
facilitating discussion in the consultation. The prototype
includes (a) a title that specifies the decision; (b) informa-
tion on the health condition and the eligible users; (c) a
summary of the options being considered; (d) evidence on
the benefits and harms of each option with probabilities
(evidence quality rated using GRADE); (e) an explicit
values clarification exercise; (f) a question soliciting the
preferred option; and (g) the SURE Test to screen for
decisional conflict and thus identify decision making needs
(Fig. 1). The prototype has several hyperlinks to additional
information including definitions, graphic representation of
probabilities, and references. The consult decision aid
meets all IPDAS qualifying and certifying criteria except
the criterion for using an implicit values-clarification
method requiring detailed descriptions of the options and
outcomes [11]. Instead, given there is ‘‘no single ‘best’
practice’’ for values clarification [20], an explicit values-
clarification method was included using a rating scale.
Probabilities are displayed using words, numbers and dia-
grams: formats known to be easier for patients to under-
stand [21, 22].
3.5 Alpha Testing with Potential Users
The consult decision aid prototype was populated with
evidence from a Cochrane Review focused on alendronate
as a treatment option for osteoporosis (Appendix, see
electronic supplementary material). Alpha testing of this
consult decision aid on alendronate was conducted with
members of the Cochrane Consumer Network (potential
patients) and staff from the Cochrane Editorial Unit to
determine acceptability and usability (Table 1) [13].
Cochrane Consumer Network members and the Editorial
Unit staff are familiar with Cochrane protocols and reviews
but unlikely to have had previous exposure to values
clarification exercises and tools to support decision mak-
ing. Eligible participants needed to be able to read English
and have computer access. Participants were interviewed in
person or via Skype. During the audio-recorded interviews,
the research assistant guided the participant through the
consult decision aid in a manner similar to which it could
be presented in a consultation and then asked questions
using a structured interview guide. Prior to the interview,
participants received a copy of the consult decision aid and
interview guide. They were told not to review it before the
interview and that it would be used during the interview.
The interview guide had seven questions from the
Preparation for Decision Making Scale [23], ten questions
from the acceptability questionnaire that has been exten-
sively used for evaluating patient decision aids during
development [24], and four common questions for usability
testing [25] (Table 2). The Preparation for Decision Mak-
ing Scale, previously validated, was shown to have high
internal consistency with alpha coefficients of 0.92–0.96,
and discriminated between patients who reported the
patient decision aid was or was not helpful [23].
Participant quantitative responses were entered into an
Excel database and analyzed descriptively using frequency
distribution. Audio recordings of interviews were tran-
scribed verbatim and qualitative comments were analyzed
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using content analysis. More specifically, the transcript was
read line by line to identify common themes that partici-
pants identified as issues affecting acceptability and/or
usability of the patient decision aid. The research team
reviewed findings and revised the prototype.
3.6 Applying the Prototype to Cochrane Reviews
The revised prototype was used to create a series of 12
consult decision aids populated with data from 12 different
Cochrane Reviews. Eligible reviews had a summary of
findings table and included two or more reasonable options
(that may have included no treatment/screening). A clini-
cian from the stakeholder committee with expertise in
patient education reviewed the description of the health
condition and options and verified accuracy of the proba-
bilities presented. As well, the clinician verified use of
plain language. Time to create the consult decision aids
was monitored.
3.7 Considerations for Embedding a Consult
Decision Aid in a Cochrane Review
Using a Delphi process [10], the stakeholder committee
was tasked with reaching consensus on the considerations
necessary for selecting which Cochrane Reviews should
have an accompanying consult decision aid. This Delphi
process involved three iterations: (1) in the first round, we
gathered suggestions based on our experiences developing
patient decision aids and creating the series of 12 consult
decision aids; (2) in the second round, committee members
individually rated each consideration on a scale from 1 to 9
in an Excel spread sheet (1 not important, 9 extremely
important) [26]; and (3) in the third round, committee
Fig. 1 Consult decision aid prototype indicating IPDAS criteria
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members discussed ratings having median differences of
three or more points and reached consensus on those that
were rated as important (e.g. rated as 7–9) [27].
4 Results
4.1 Participant Characteristics
Eleven members of the Cochrane Consumer Network and
three staff from the Cochrane Editorial Unit consented to
participate (Table 1). Two were male and 12 were female;
ages 30–60 years old with a range of education levels (e.g.,
high school only to university graduate degrees). Partici-
pants were employed (e.g., health professionals, man-
agers), retired, or unemployed with several receiving
disability insurance. Although not required, ten had
previous experience (personal, professional or family
member) with the health condition in the consult decision
aid (i.e., osteoporosis).
4.2 Acceptability and Usability
Most participants rated the details provided in each section
of the consult decision aid as good or very good (Table 2).
Ten of 14 rated the presentation of information as balanced
and four rated it as slightly slanted toward taking treatment.
Twelve participants thought the words made sense and
icons were understood. Regarding information content,
seven indicated that there was the right amount, six wanted
more information, and one indicated there was too much.
On the Preparation for Decision Making scale, most par-
ticipants indicated it was helpful for preparing to make
decisions with the clinician (Table 3). Thirteen participants
Fig. 1 continued
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indicated that it was suitable for use in consultations with
their clinician and were willing to use it and/or tell
someone else about it (Table 2). One consumer participant
consistently rated the questions about acceptability and
usability as low (Table 2); describing inadequate time with
the clinician in the consultation to be able to use the consult
decision aid as the main reason influencing his responses.
4.3 Qualitative Feedback with Actions Taken
(Table 4)
The suggestion to use more plain language (e.g., decline,
contraindication, bisphosphonate, harm–benefit ratio) was
addressed by changing to simpler words. Where words
could not be changed, a link to the definition was added
(e.g., best estimate, GRADE, osteoporosis). Topics/ques-
tions for patients to ask their clinician were added includ-
ing safety with other drugs, long-term use of drugs, costs,
changes in side effects over time, how to manage side
effects, and allergies. Although the font was described as
too small, an electronic version would allow the font size to
be scalable. The font size in the prototype was chosen to
ensure a one-page format when printed. More white space
was added. The X icon used for the option of declining the
active option was described as too strong and was changed
to a size more consistent with other icons. Suggestions for
using the consult decision aid in the consultation were
developed (see Box 1).
Some suggestions in qualitative comments were not
addressed. For example, in step 2 we did not add a full list
of options because the options were limited to those
described in the Cochrane Review. If Cochrane Reviews
provided a full list of options, this information could
consistently be added into the consult decision aid. Visual
aspects and images would need to be improved by a gra-
phic designer during the publishing process. Confidence
intervals were not added as they make the figures too busy
and are already acknowledged within the GRADE rating.
4.4 Applying the Prototype to a Range of Reviews
In March 2014, there were 975 Cochrane Reviews with sum-
mary of findings tables. Twelve Cochrane Reviews were pur-
posefully chosen to represent a range of decisions about
surgery, screening, or medications. The average time for cre-
ating a consult decision aid was 3 h by a research assistant plus
1 h for verification by a clinician on the stakeholder committee.










Highest level of education
High school 3
Community college 4
University undergraduate degree 4
University graduate degree 3
Employment status
Employed as a health professional 3









Box 1 Tips on using the consult decision aid
in clinical practice
Use the consult decision aid interactively in the con-
sultation with patients answering questions and adding
information specific to their own situation
Review the options (Step 2), and the benefits and
harms of each option (Step 3a)
Ask patients to identify other features of options that
are important to them (Step 3b)
Rate the level of importance on a scale of 0–5 to help
patients weigh the benefits and harms of options to reach
a preferred option (Step 3b)
Discuss other information to consider (Step 3c) to
tailor the discussion to the individual patient’s situation
(e.g., allergies, changes in side effects over time, costs,
safe with other drugs, length of treatment, ways to
manage side effects)
Based on the discussion in Step 3, ask patients which
option they prefer (Step 4)
Screen for decision-making needs by asking the four
questions (Step 5)
Provide extra information in the links such as defi-
nitions, graphical representation of probabilities, inter-
pretation of the SURE test results, developers,
references, and interpretation of the GRADE rating
(GRADE is more for the clinician)
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4.5 Considerations for Embedding Consult Decision
Aids in Cochrane Reviews
The stakeholder committee reached consensus on three
characteristics of Cochrane Reviews that make it easier to
develop a consult decision aid and seven circumstances
indicating when it is relevant to include a consult decision
aid. It is easier to create a consult decision aid when a
Cochrane Review provides a summary of findings table,
describes the health condition and interventions in the plain
language summary, and is focused on a topic involving two
reasonable options (including no treatment/screening). It is
relevant to include a consult decision aid when the
Cochrane Review (a) provides evidence on benefits and
harms; (b) is focused on an important topic to patients and
clinicians; (c) is about a topic that occurs commonly in
clinical practice; (d) involves trade-offs between benefits
and harms; (e) is a controversial topic (e.g., strong views
Table 2 Consult decision aid
acceptability and usability
Items Frequency (N = 14)
Amount of information in the consult decision aid
Much less than I wanted 2
A little less than I wanted 4
About right 7
Little more than I wanted 0
Much more than I wanted 1
Balanced presentation of information in the consult decision aid
Clearly slanted towards taking the treatment 0
Slightly slanted towards taking the treatment 4
Completely balanced 10
Slightly slanted towards not taking the treatment 0








Words in the PtDA make sense
Yes 12
No 2
PtDA fit with patients’ discussions with physician, nurse or pharmacist
Yes, as it is 12
Yes, but with some alteration 1
No 1
Willingness to use PtDA and/or tell someone about it
Yes 13
No 1
Clarity of the information presented by section Poor Fair Good Very good
What is the [condition]? 0 2 6 6
What are the treatment options? 1 2 3 8
Weighing the benefits and harms of each option 0 2.5 7.5 4
Which option do you prefer? 0 0 4 10
More information 0 3 3 8
Information on funding/authors 0 1 4 9
References 0 0 7 7
PtDA patient decision aid
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for and against the options); (f) involves a decision that is
irreversible (e.g., surgery, genetic testing); and/or (g) has
recently been updated (e.g.,\5 years old).
5 Discussion
Using a systematic process, we developed a consult deci-
sion aid prototype that was found to be acceptable for
facilitating shared decision making during the consultation
and feasible to use for translating evidence from Cochrane
Reviews. We showed that the Ottawa Decision Support
Framework and IPDAS approaches for developing patient
decision aids were flexible enough to develop this proto-
type [11]. Although the participants rated the consult
decision aid as acceptable and usable, most wanted more
information. In addition, the prototype was easily applied
to create a series of 12 consult decision aids from 12 dif-
ferent Cochrane Reviews with the process taking on
average 4 h per consult decision aid. Finally, the stake-
holder committee determined three characteristics of
Cochrane Reviews making it easier to create consult
decision aids and seven circumstances indicating when it is
relevant to create one. These results lead us to four main
points of discussion.
First, our findings demonstrate that the Ottawa Decision
Support Framework provides a clear approach for pro-
ducing these briefer patient decision aids for use in con-
sultations [17, 18, 28]. In previous trials of patient decision
aids developed using the Ottawa Framework, patients had,
for example, improved knowledge, improved realistic
expectations, decreased decisional conflict, and rated the
decision aid as acceptable [17, 28–34]. A toolkit for
developing patient decision aids and consult decision aids
using the Ottawa Framework is available in a free-of-
charge online training tutorial [35]. Similar to other newer
approaches to building decision aids for use in consulta-
tions (e.g., decision box, option grids), further research is
required to determine their effectiveness [6].
Second, briefer one-page patient decision aids with
more limited information on options shift the focus from
providing detailed information on options to being more
oriented to the process of decision making. The ultimate
aim of the consult decision aid is to facilitate discussion of
the evidence on the options and on the patients’ values
during a shared decision making process. Of eight ran-
domized controlled trials evaluating previously developed
patient decision aids designed for use within the consul-
tation, seven reported improved patient–clinician commu-
nication and one trial found no difference when compared
with usual care [6]. Hence, the new consult decision aid
should stimulate patient–clinician discussion within the
consultation on the options, prompt them to consider other
information tailored to the patient’s personal situation,
provide the patient opportunities to ask other questions; for
example, how does this new medication fit with their other
medications and health conditions (e.g., allergies), plus
discuss possible side effects and ways they could be
managed. A systematic review has indicated that question
prompt lists are effective interventions for improving
communication and cognitive outcomes [36].
Third, expanding the information in the consult decision
aid to respond to participants’ feedback must be considered
cautiously. The consult decision aid needs to provide
enough information to improve patients’ knowledge while
avoiding too much information that can interfere with its
usability within clinical consultations. When more detailed
decision aids were compared with briefer decision aids in
trials, patients had slightly higher knowledge but the dif-
ferences were small [37]. A unique feature of this consult
decision aid is its layered presentation of information with
one main page and links to additional information. The
main page provides brief information on options, helps
clarify patients’ values for outcomes, and screens for
decisional conflict to indicate unmet decisional needs.
Current links provide information on definitions but could
be expanded to provide links to more detailed sources of
information. Providing layers of information allows
Table 3 Participants’ ratings on the Preparation for Decision Making Scale [23]
Items Frequency (N = 14)a
Not at all A little Somewhat Quite a bit A great deal
1. Help patients recognize a decision needs to be made 0 0 1 3 10
2. Prepare patients to make a better decision 0 0 2.5 4.5 7
3. Help patients think about the pros/cons of options 0 1 0 6 7
4. Help patients think about which pros/cons are most important 0 1.5 1.5 8 3
5. Help patients know that the decision depends on what matters most to them 0 0 0 7 7
6. Help patients organize their own thoughts about the decision 0 0 3 5.5 5.5
7. Help patients ask questions to their doctor 0 2 0 3 9
a Half numbers were used when participants rated between items
578 D. Stacey et al.
patients after the consultation to obtain the amount of
information they desire. Using internet-based delivery of
the consult decision aids would enable easier access to
other relevant information resources [38].
Fourth, efficient or automated processes could be
developed to transfer information from Cochrane Reviews
into the consult decision aid prototype and facilitate
updates. After applying the prototype to 12 Cochrane
Reviews, we established a set of considerations for
selecting Cochrane Reviews suitable for creating consult
decision aids. Next, these considerations need to be applied
by people less familiar with patient decision aid develop-
ment and they could be applied to non-Cochrane system-
atic reviews. Given current initiatives to automate
systematic reviews [39], it may also be possible to auto-
mate the creation of these consult decision aids. The
Cochrane Library is in the process of establishing
automation for some processes. For example, Evidence
Pipeline was initiated to redirect primary studies auto-
matically to their respective review groups, in order to
Table 4 Summary of qualitative findings on the consult decision aid about alendronate as a treatment option for osteoporosis
Categories Comments/suggestions Response
Plain language Use plain language (e.g., harm–benefit ratio,
contraindications, decline)
Changed to simpler words
Alendronate ‘may’ … is unclear No change because this is accurate information
Remove ‘reasons to’ No change; features are not always benefits
Unsure if all will understand the information No change; for use in the consultation
Unclear what ‘best estimate’ means Added hyperlink to more information
Print size Add more space Added more space on internet version
Enlarge font for GRADE rating No change; information is for the clinician
Enlarge font overall No change; can modify font with browser settings
Make footer easier to read Changed color from gray to black font
Logical
layout/format
Need printable version Electronic and paper versions are planned
Improve designs for images Images to be improved during publishing
X in ‘decline the option’ is too strong X used for years in DAs; changed color/font of X to balance with
other icons
Move ‘SURE test’ sooner No change; selecting kept after comparing options
Write from patient perspective (e.g. ‘I’ instead of
‘you’)




GRADE should be explained Added more details in a hyperlink
Unclear for ‘how much does this matter’ Added ‘to you’
Osteopenia does not equal osteoporosis Removed osteopenia as it was not necessary
Missing information Interaction with other drugs Added to list of other information to consider
Long-term use of medicine: benefits/harms,
changes in side effects over time
Added to list of other information to consider
Significance of harms and outcomes Added to list of other information to consider
Confidence intervals No change; not necessary for IPDAS criteria
Allergies Added to list of other information to consider
Cochrane and development of DA Added in user manual
More information on side effects Added to list of other information to consider
Full list of options Identified as a limitation
List of questions to discuss with doctor Added based on other information to consider
Too much
information
If they have osteoporosis, do you need description
in Part I
Required by IPDAS but not necessary to go through in a consult;
added in manual on how to use it
Need for data entry: if they are doing it with the
doctor, why write it down?
For values clarification, it is better if the tool is interactive; made
explicit in user manual
Remove references Required by IPDAS criteria; remained as hyperlink
Instructions Be more explicit on how to use the links Added to user manual and provided blue underlines
Provide instructions on using it Added in user manual
DA decision aid, IPDAS International Patient Decision Aid Standards
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facilitate and streamline Cochrane Review updates [40]. As
well, the PICOtron is being used to extract information
from reviews to produce summaries of the evidence [41].
Given that Cochrane evidence is currently reported in 12
languages, there is the potential to create consult decision
aids in multiple languages which would better address
health policies mandating their use in clinical practice [42].
There are a few limitations and strengths to consider.
The consult decision aids developed from Cochrane
Reviews are limited by the amount of information pre-
sented in the reviews. For example, many Cochrane
Reviews identified a limited number of options but this
could easily be changed in reviews by, at a minimum,
including a fuller list of options. Second, the evaluation
from potential users (who happened to be familiar with the
topic) was simulated and conducted as part of the devel-
opment process. Hence, further evaluation is required to
determine their effectiveness in clinical consultations and
how it compares to a more detailed decision aid. Third,
participants evaluated mocked-up word documents and
ideally the consult decision aids should be hosted online to
provide easy access to hyperlinked information and scaling
of fonts. Fourth, the 12 consult decision aids were not
reviewed by a panel of topic experts. Given that Cochrane
Review teams include topic experts, it is possible to
incorporate a topic panel review into the development
process. A subsequent study could evaluate the added value
of topic expert review by determining the accuracy of
information presented in the consult decision aid with and
without expert review. These 12 consult decision aids
require further evaluation by potential users, ideally
including users with a broader range of characteristics.
Finally, the acceptability evaluation was based on the
consult decision aid prototype applied to one Cochrane
Review and some participants’ comments were specific to
this clinical decision. Strengths were the various charac-
teristics of participants including several with secondary
school education only and the relevance of most of their
feedback across decisions.
6 Conclusions
The consult decision aid prototype uses a one-page brief
format for presenting evidence from Cochrane Reviews to
facilitate shared decision making in the consultation. This
prototype meets the proposed minimal qualifying and
certifying criteria from the IPDAS Collaboration. Health
consumers and Cochrane editorial staff found it was
acceptable and rated it positively for usability. Several
suggestions were used to strengthen the amount and display
of information. Application of the prototype to a series of
Cochrane Reviews demonstrated the ability to apply it to a
range of different health topics and efficiencies in creating
consult decision aids. Issues to consider are the primary
aim of the decision aid (e.g., information plus support
versus process-oriented), the amount of information to
provide and/or link to, and ways to automate the process to
further improve efficiencies in creating patient decision
aids. Consult decision aids were easier to create when there
was a summary of findings table, a plain language sum-
mary, and a treatment/screening decision with two or more
reasonable options (including no treatment/screening).
Seven circumstances were identified for determining
Cochrane Reviews relevant for including consult decision
aids. These considerations for embedding consult decision
aids in Cochrane Reviews are likely transferable across
other types of high quality systematic reviews. Future
studies will evaluate implementation of consult decision
aids.
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